On Jun. 4, 2020, INOVIO and Seoul National University Hospital announced a partnership to start a Phase 1/2 clinical trial of INOVIO’s COVID-19 vaccine INO-4800 in South Korea.

The 2-stage trial of INO-4800, the first clinical study of COVID-19 vaccine in Korea, assessed the safety, tolerability, and immunogenicity of the candidate vaccine in 40 healthy adults aged 19-50 years, and was further expanded to enroll an additional 120 people aged 19-64 years.